HK1207959A1 - Stimulation of ovarian follicle development and oocyte maturation - Google Patents

Stimulation of ovarian follicle development and oocyte maturation

Info

Publication number
HK1207959A1
HK1207959A1 HK15107135.4A HK15107135A HK1207959A1 HK 1207959 A1 HK1207959 A1 HK 1207959A1 HK 15107135 A HK15107135 A HK 15107135A HK 1207959 A1 HK1207959 A1 HK 1207959A1
Authority
HK
Hong Kong
Prior art keywords
stimulation
ovarian follicle
oocyte maturation
follicle development
development
Prior art date
Application number
HK15107135.4A
Other languages
Chinese (zh)
Inventor
Aaron J W Hsueh
Yuan Cheng
Masashi Deguchi
Kazuhiro Kawamura
Original Assignee
Intellectual Property Man Ct In The
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellectual Property Man Ct In The filed Critical Intellectual Property Man Ct In The
Publication of HK1207959A1 publication Critical patent/HK1207959A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pregnancy & Childbirth (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Finger-Pressure Massage (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
HK15107135.4A 2012-09-13 2015-07-27 Stimulation of ovarian follicle development and oocyte maturation HK1207959A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261700799P 2012-09-13 2012-09-13
US201361778024P 2013-03-12 2013-03-12
PCT/US2013/059800 WO2014043568A1 (en) 2012-09-13 2013-09-13 Stimulation of ovarian follicle development and oocyte maturation

Publications (1)

Publication Number Publication Date
HK1207959A1 true HK1207959A1 (en) 2016-02-19

Family

ID=50278733

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15107135.4A HK1207959A1 (en) 2012-09-13 2015-07-27 Stimulation of ovarian follicle development and oocyte maturation

Country Status (13)

Country Link
US (1) US20150231209A1 (en)
EP (1) EP2895185B1 (en)
JP (1) JP2015531787A (en)
CN (1) CN105025912B (en)
AU (1) AU2013315154B2 (en)
BR (1) BR112015005653A8 (en)
CA (1) CA2924052A1 (en)
EA (1) EA201590549A1 (en)
HK (1) HK1207959A1 (en)
IL (1) IL237698A0 (en)
MX (1) MX2015003233A (en)
NZ (1) NZ706889A (en)
WO (1) WO2014043568A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104130972B (en) * 2014-07-09 2017-03-22 南京医科大学 Primordial follicle activator and applications thereof
CA2995684A1 (en) * 2014-09-10 2016-03-17 The Board Of Trustees Of The Leland Stanford Junior University Stimulation of ovarian follicle development and oocyte maturation
CN106177912B (en) * 2016-07-18 2019-06-18 暨南大学 The application of CTRP3 albumen
US11976302B2 (en) 2017-05-06 2024-05-07 Upside Foods, Inc. Compositions and methods for increasing the culture density of a cellular biomass within a cultivation infrastructure
JP7313059B2 (en) * 2017-05-08 2023-07-24 メハリー メディカル カレッジ Hydroxyurea for strengthening sperm cells
US11479792B2 (en) 2017-07-13 2022-10-25 Upside Foods, Inc. Compositions and methods for increasing the efficiency of cell cultures used for food production
US11192865B2 (en) * 2017-08-21 2021-12-07 Vivace Therapeutics, Inc. Benzosulfonyl compounds
EP3793551A4 (en) 2018-05-16 2022-01-26 Vivace Therapeutics, Inc. Oxadiazole compounds
CN108753699B (en) * 2018-06-19 2021-04-30 青岛农业大学 Method for remedying in vitro development damage of porcine oocytes by zearalenone
JP2020050625A (en) * 2018-09-27 2020-04-02 株式会社北里コーポレーション Ovarian tissue transplantation method and follicle activation method
CN114703121A (en) * 2022-03-29 2022-07-05 广西大学 Activation medium for buffalo ovary cortex in-vitro culture and in-vitro culture method
CN116375861B (en) * 2023-05-16 2023-08-08 成都大熊猫繁育研究基地 Anti-panda LIF monoclonal antibody, hybridoma cell strain and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850984B2 (en) * 2000-02-15 2010-12-14 The General Hospital Corporation Protection of the female reproductive system from natural and artificial insults
US20070203098A1 (en) 2004-04-06 2007-08-30 Semafore Pharmaceuticals, Inc. Pten Inhibitors
CN101932331B (en) * 2008-01-17 2012-10-24 刘奎 Methods for in vitro maturation of ovarian follicles
US20100191040A1 (en) * 2009-01-23 2010-07-29 The Board Of Trustees Of The Leland Stanford Junior University Manipulation of ovarian primordial follicles
JP5663841B2 (en) * 2009-02-23 2015-02-04 富士レビオ株式会社 Medium for inducing differentiation into bone cells and method
MX2014007182A (en) * 2011-12-14 2015-04-17 Univ Leland Stanford Junior Stimulation of ovarian follicle development and oocyte maturation.
WO2013188138A1 (en) * 2012-06-11 2013-12-19 The Regents Of The University Of California Inhibitors of hippo-yap signaling pathway

Also Published As

Publication number Publication date
MX2015003233A (en) 2015-11-16
EA201590549A1 (en) 2015-08-31
JP2015531787A (en) 2015-11-05
AU2013315154B2 (en) 2018-01-18
CA2924052A1 (en) 2014-03-20
NZ706889A (en) 2016-07-29
EP2895185B1 (en) 2019-07-10
AU2013315154A1 (en) 2015-04-30
CN105025912A (en) 2015-11-04
BR112015005653A8 (en) 2018-01-30
EP2895185A4 (en) 2016-07-06
WO2014043568A1 (en) 2014-03-20
CN105025912B (en) 2018-08-21
EP2895185A1 (en) 2015-07-22
IL237698A0 (en) 2015-05-31
BR112015005653A2 (en) 2017-08-22
US20150231209A1 (en) 2015-08-20

Similar Documents

Publication Publication Date Title
HK1207959A1 (en) Stimulation of ovarian follicle development and oocyte maturation
IL233073B (en) Stimulation of ovarian follicle development and oocyte maturation
HK1208439A1 (en) 5-azaindazole compounds and methods of use 5-
IL233476B (en) Carbamate compounds and methods of making and using same
GB201223276D0 (en) Antibodies and methods of producing same
IL238227A0 (en) Anti-c16orf54 antibodies and methods of use thereof
EP2835369A4 (en) Crystal form of cabazitaxel and preparation method thereof
IL233317A0 (en) Anti-lrp5 antibodies and methods of use
HK1203954A1 (en) Heteroaryl compounds and methods of use thereof
EP2938632A4 (en) Anti-granulysin antibodies and methods of use thereof
HK1210176A1 (en) Crystal form of chidamide, preparation method and use thereof
HK1209432A1 (en) Anti-jagged antibodies and methods of use
HRP20181000T1 (en) Methods of treating hair related conditions
EP2882422A4 (en) Neuroprotective liposome compositions and methods for treatment of stroke
EP2850895A4 (en) Methods and apparatuses for enabling provision of an additional special subframe configuration
PL2684611T3 (en) Mixer and method of atomizing
HK1203494A1 (en) Heteroaryl compounds and methods of use thereof
EP3191117A4 (en) Stimulation of ovarian follicle development and oocyte maturation
EP2847193A4 (en) Heteroaryl compounds and methods of use thereof
IL234492A (en) Crystal forms of 5α-androstane-3β,5,6β-triol and preparation methods therefor
EP2844219A4 (en) Sensitization composition and method of use
HK1210143A1 (en) Crystal forms of azetidinone compounds and preparing methods thereof
ZA201405644B (en) Weatherised minerals and methods of making and using same